← Back to Screener
Avidity Biosciences, Inc. Common Stock (RNAM)
Price$0.00
Growth ScoreA
Favorite Metrics
VGM Score86.22
Market Capitalization$11.30B
All Metrics
Revenue Growth (3Y)5.31%
Cash Flow / Share (Quarterly)$-4.06
Net Profit Margin (TTM)-2634.59%
EPS (TTM)$-4.17
10-Day Avg Trading Volume16.84M
EPS Excl Extra (TTM)$-4.17
Revenue Growth (5Y)36.26%
EPS (Annual)$-2.89
ROI (Annual)-22.62%
Net Profit Margin (5Y Avg)-1796.59%
Cash / Share (Quarterly)$12.78
Revenue Growth QoQ (YoY)434.03%
ROA (Last FY)-20.61%
Revenue Growth TTM (YoY)106.27%
EBITD / Share (TTM)$-4.64
ROE (5Y Avg)-28.11%
Operating Margin (TTM)-2934.90%
Cash Flow / Share (Annual)$-2.57
P/B Ratio5.99x
Net Income / Employee (Annual)$-630,700
Net Interest Coverage (TTM)-2.35x
ROA (TTM)-33.70%
EPS Incl Extra (Annual)$-2.89
Current Ratio (Annual)15.73x
Quick Ratio (Quarterly)11.48x
3-Month Avg Trading Volume16.84M
Revenue / Employee (TTM)$40,800
P/S Ratio (Annual)1036.80x
Asset Turnover (Annual)0.01x
52-Week High$73.04
Operating Margin (5Y Avg)-1959.94%
EPS Excl Extra (Annual)$-2.89
CapEx CAGR (5Y)96.69%
Quick Ratio (Annual)15.61x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.57x
Revenue / Share Growth (5Y)13.23%
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$21,300
Pretax Margin (Annual)-2957.71%
Cash / Share (Annual)$12.52
Net Income / Employee (TTM)$-1,075,900
ROE (Last FY)-22.62%
EPS Basic Excl Extra (Annual)$-2.89
Receivables Turnover (TTM)19.72x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.17
ROI (TTM)-37.70%
P/S Ratio (TTM)541.40x
Pretax Margin (5Y Avg)-1796.59%
Revenue / Share (Annual)$0.10
EPS Normalized (Annual)$-2.89
ROA (5Y Avg)-24.50%
Net Profit Margin (Annual)-2957.71%
EBITD / Share (Annual)$-3.37
Operating Margin (Annual)-3477.43%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-28.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.17
Pretax Margin (TTM)-2634.59%
P/FCF (Annual)5021.33x
Revenue / Share (TTM)$0.15
ROE (TTM)-37.70%
52-Week Low$72.75
gGradeA
vgmGradeA
Show chart for
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
3.76
3.50
3.50
3.50
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNAMAvidity Biosciences, Inc. Common Stock | — | A | — | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Avidity Biosciences is a biopharmaceutical company developing a novel class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company has three programs in registrational clinical trials: Del-desiran for myotonic dystrophy type 1, Del-zota for Duchenne muscular dystrophy, and Del-brax for facioscapulohumeral muscular dystrophy.